Literature DB >> 22094280

Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases.

Christoph Nitsche1, Christian Steuer, Christian D Klein.   

Abstract

The 3-aryl-2-cyanoacrylamide scaffold was designed as core pharmacophore for inhibitors of the Dengue and West Nile virus serine proteases (NS2B-NS3). A total of 86 analogs was prepared to study the structure-activity relationships in detail. Thereby, it turned out that the electron density of the aryl moiety and the central double bond have a crucial influence on the activity of the compounds, whereas the influence of substituents of the amide residue is less relevant. The para-hydroxy substituted analog was found to be the most potent inhibitor in this series with a K(i)-value of 35.7 μM at the Dengue and 44.6 μM at the West Nile virus protease. The aprotinin competition assay demonstrates a direct interaction of the inhibitor molecule with active centre of the Dengue virus protease. The target selectivity was studied in a counterscreen with thrombin and found to be 2.8:1 in favor of DEN protease and 2.3:1 in favor of WNV protease, respectively.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22094280     DOI: 10.1016/j.bmc.2011.10.061

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  13 in total

1.  Tractable synthesis of multipurpose screening compounds with under-represented molecular features for an open access screening platform.

Authors:  Felix Wilde; Edgar Specker; Martin Neuenschwander; Marc Nazaré; Anja Bodtke; Andreas Link
Journal:  Mol Divers       Date:  2014-04-01       Impact factor: 2.943

2.  C-terminal residue optimization and fragment merging: discovery of a potent Peptide-hybrid inhibitor of dengue protease.

Authors:  Mira A M Behnam; Christoph Nitsche; Sérgio M Vechi; Christian D Klein
Journal:  ACS Med Chem Lett       Date:  2014-07-18       Impact factor: 4.345

3.  Dengue Virus NS2B/NS3 Protease Inhibitors Exploiting the Prime Side.

Authors:  Kuan-Hung Lin; Akbar Ali; Linah Rusere; Djade I Soumana; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

4.  Inhibitors of Dengue virus and West Nile virus proteases based on the aminobenzamide scaffold.

Authors:  Sridhar Aravapalli; Huiguo Lai; Tadahisa Teramoto; Kevin R Alliston; Gerald H Lushington; Eron L Ferguson; R Padmanabhan; William C Groutas
Journal:  Bioorg Med Chem       Date:  2012-05-10       Impact factor: 3.641

5.  Nanoparticular Inhibitors of Flavivirus Proteases from Zika, West Nile and Dengue Virus Are Cell-Permeable Antivirals.

Authors:  Barbara Schroeder; Peter Demirel; Christina Fischer; Enaam Masri; Stephanie Kallis; Lisa Redl; Thomas Rudolf; Silke Bergemann; Christoph Arkona; Christoph Nitsche; Ralf Bartenschlager; Jörg Rademann
Journal:  ACS Med Chem Lett       Date:  2021-11-29       Impact factor: 4.345

Review 6.  Targeting the protease of West Nile virus.

Authors:  Saan Voss; Christoph Nitsche
Journal:  RSC Med Chem       Date:  2021-05-26

7.  Dengue Protease Substrate Recognition: Binding of the Prime Side.

Authors:  Kuan-Hung Lin; Ellen A Nalivaika; Kristina L Prachanronarong; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  ACS Infect Dis       Date:  2016-09-22       Impact factor: 5.084

Review 8.  The flavivirus protease as a target for drug discovery.

Authors:  Matthew Brecher; Jing Zhang; Hongmin Li
Journal:  Virol Sin       Date:  2013-11-14       Impact factor: 4.327

9.  New binding site conformations of the dengue virus NS3 protease accessed by molecular dynamics simulation.

Authors:  Hugo de Almeida; Izabela M D Bastos; Bergmann M Ribeiro; Bernard Maigret; Jaime M Santana
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

Review 10.  West Nile virus drug discovery.

Authors:  Siew Pheng Lim; Pei-Yong Shi
Journal:  Viruses       Date:  2013-12-03       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.